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Candida-specific IgG4 and asthma
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Abstract: Serum levels of Candida-specific IgG4 antibodies were examined in 66
patients with bronchial asthma, relating to patient age and asthma severity.
1. The levels of Candida-specific IgG 4 antibodies were the highest in patients with
60+years of age, compared to the levels in cases with 0-39 and 40-59 years of age.
2. In cases with 40 - 59 years of age, the levels of Candida-specific IgG 4
were significantly higher in cases with long-term steroid therapy (severe intractable
asthma) than in cases without steroid regimen.
The results suggest that increased levels of Candida-specific IgG4 were ob-
served in relation to patient age and asthma severity.
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Introduction
Candida albicans is one of the most impor-
tant allergens in bronchial asthma. Candida as
an allergen can induce histamine release from
basophilic leucocytes through IgE receptors1,2),
but the release of histamine induced by Can-
dida is somewhat different from the release
by house dust-mite and anti-IgE 3,4), sug-
gesting participation of IgG antibodies
in Candida-induced reaction 2,5) •
The role of IgG 4 antibodies, which are
capable of sensitising human skin for 2-4
hours only6) and described as IgG short-
term sensitising (IgG S-TS) by Parish7) ,
is still controversial. It has been suggested
that IgG4 as well as IgE may participate
in immediate allergic reactions. However, any
results about participation of IgG4 III
allergen-triggered histamine release and anti-
IgG4 - induced release of histamine have not
been shown8,9) . On the other hand, it has
been reported that IgG4 could act as a
blocking antibody in natural allergen expo-
sures and hyposensitization treatment10,1l).
A question as to whether IgG4 is a sensi-
tising or a blocking antibody, or both still
remaIll.
In this report serum levels of Candida-
specific IgG4 antibodies were measured in
patients with bronchial asthma, and relation-
ship of the levels to patient age and asthma
2severity was discussed.
Subjects and Methods
Subjects were 66 patients with bronchial
asthma, 35 females and 31 males, including
15 cases with steroid-dependent intractable
asthma. The subjects Were divided into three
age groups ; 0 to 39 (group A), 40 to 59
(group B), 60 + years of age (group C).
Serum levels of specific IgG4 against
Candida albicans were estimated by a ELISA
method12) •
Results
1. Relationship to patient age.
A significant difference was not present
in serum levels of Candida-specific IgG4
bet¥.een cases of group A and B. The
levels of Candida-specific IgG4 were signif-
icantly higher in cases of group C than m
cases of group B (p<0.05) (Table O.
Table 1. Serum levels of Candida-specific
IgG4 antibodies m relation to
patient age
Patient age, No of
Serum levels of specific IgG4 (U/ml)
years, Mean :t SD Range
0-39 12 14.5.13.7 2.5-48.0
40-59 21 13.2 :t 15.6 2.5-62.0
60+ 33 25.9 • 24.2 2.5-80.0
2. Relationship to asthma severity.
Serum levels of Candida-specific IgG4
were 11.9±14.3U/me (Mean±SD) in cases
without steroid regimen, and 21.0±2.0U/m£
in c(lses with long-term steroid therapy (ST
cases) (severe intractable asthma) of group
A. The levels were higher in ST cases,
although the difference was not significant.
Compared to the levels of Candida-specific
IgG4 (7.2 ± 5. 2U/ m.e) in cases without steroid
regimen, the levels were significantly higher
(32.5±21.1U/m.e) in ST cases of group B
(p<O.OOl). No significant difference was
present m Candida-specific IgG4 between
cases without steroid regimen (24.5 ± 23.4
U/m£) and ST cases (29.4±26.0U/m£) of
group C (Fig. 1).
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Fig. 1. Serum levels of Candida-specific
IgG4 antibodies m relation to
asthma severity. ( c:::=J) : cases
without steroid regimen, ( _) :
cases with long-term steroid therapy
Discussion
It has been thought that IgG4 partici-
pates m immediate allergic reactions. At
first, it has been noticed that IgG4 as
well as IgE acts on allergic reactions as
a sensitising antibody, as previously reported
by Parish7) • IgE, however, can induce his-
tamine release from basophils, but not IgG49).
After then IgG4 has been demonstrated to act
as a blocking antibody in natural allergen
exoposures and hyposensitization treatmentlO,!l)
In this report an increase in Candida-
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anaphylactic
sera. Lancet
specific IgG4 was observed in relation to
patient age and asthma severity. Our previous
studies showed that serum levels of Candida-
specific IgG m patients with bronchial
asthma increased with aging13). The levels
of Candida-specific IgG4 correlate to a
certain extent with aging. The levels were
higher in cases with 60 + years of age, com-
pared to cases with 0 -39 and 40-59. The
results suggest that higher levels of specific
IgG4 do not lead to participation of Can-
dida in the onset mechanisms of bronchial
asthma in elderly.
On the other hand, it 1S possible to spec-
ulate that higher levels of Candida-specific
IgG 4 in patients with severe intractable
asthma correlate with participation of the
allergen-mediated reactions in the onset mech-
anisms when patient age is between 40 and 59
years. In cases with 0 - 39 years of age,
higher levels of specific IgG4 were ob-
served in severe intractable cases. But no
significant difference was found because the
number of these cases was too small, only
two cases.
The results obtained here suggest that
specific IgG4 acts as a sens1tlsmg anti-
body when Candida is an allergen.
References
1. Tanizaki, Y., Komagoe, H., Sudo, M.,
Morinaga, H., Kitani, H., Nakagawa, S.,
Matsuoka, T., Tada, S., Takahashi, K.
and Kimura, 1. : Candida-induced histamine
release from basophils. Relationship to
house dust - and anti-IgE-induced se-
cretion. Acta Med. Okayama, 39: 191-
197, 1985.
2. Tanizaki, Y., Komagoe, H., Sudo, M.,
Kitani, H., Nakagawa, S., Tada, S.,
Takahashi, K. and Kimura, 1. : Basophil
histamine release induced by Candida
albicans. Relation to specific IgE and
IgG antibodies. Jpn J. Allergol., 34
: 422 -427, 1985.
3. Tanizaki, Y., Komagoe, H., Morinaga,
H., Kitani, H., Goda, Y. and Kimura,
1. Allergen and anti-IgE-induced
histamine release from whole blood. Int.
Archs Allergy Appl. Immunol., 73 : 141-
145, 1984.
4. Tanizaki, Y., Komagoe,H., Sudo, M.,
Morinaga, H., Kitani, H., Nakagawa, S.,
Takahashi, K. and Kimura, 1. : Reactivity
of sensitized human basophils as expressed
by histamine release. Jpn J. Allergol.,
33 : 463 -467, 1984.
5. Tanizaki, Y., Komagoe, H., Sudo, M.,
Morinaga, H., Kitani, H. and Kimura, 1.
: Comparison of basophil histamine release
induced by the cross-linking of IgE re-
ceptors. Acta Med. Okayama, 39: 441-
446, 1985.
6. Pepys, J., Parish, W. K, Stenius-
Aarniala, B. and Wide, L. Clinical
correlation between long-term (IgE) and
short-term (IgG S-TS) anaphylactic anti-
bodies in atopic and 'nonatopic' subjects
with respiratory allergic disease. Clin.
Allergy., 9 : 645-648, 1979.
7. Parish, W. K : Short-term
IgG antibodies m human
II : 591-592, 1970.
8. Van Toorenenbergen, A. W. and Aalberse,
R. C. : IgG4 and passive sensitization
of basophil leukocytes. Int. Archs Allergy
Appl. Immunol., 65 : 432-439, 1981.
9. Van Toorenenbergen, A. W. and Aalberse,
R. C. : IgG4 and release of histamine
from human peripheral blood leukocytes. Int.
Archs Allergy Appl. Immunol., 67 : 117-
122, 1982.
4 環境病態研報告　62，1991
10．　Van　der　Giessen，　M．，　Homan，　W．　L．，
　Van　Kernebeek，　G．，　Aalberse，　R．C．
　and　Dieges，　P．　H．　：　Subclass　typing　of
　IgG　antibodies　formed　by　grass　pollen－
　allergic　patients　during　immunotherapy．　lnt．
　Archs　Allergy　Appl．　lmmunol．，　50　：　625’
　640，　1976．
11．　Aalberse，　R．　C．，　Van　der　Gaag，　R．
　and　Van　Leeuwen，　J．　：　Serology　aspects
　of　lgG　antibodies．　1．　Prolonged　immuni－
　2ation　results　in　an　lgG　一restricted
　response．　J．　lmmu，nol．，　130　：　722－726，　1983．
12．　Engvall，　E．　and　Perlmann，　P．　一：　Enzyme－
　liked　immunosorbent　assay．　ELISA．皿．
Quantitation　of　specific　antibadies　by
　emzyme－labeled　anti－immunoglobulinin
　antigen－coated　tubes．　J．　lmmunol．，　109　：
　129－138，　1972．
13．　Tanizaki，　Y．，　Komagoe，　H．，　Sudo，　M．，
　Kitani，　H．，　Nakayama，　K．，　Tada，　S．，
　Takaha hi，　K．　and　Kimura，　1．　：　Character－
　istics　of　Candida　albicans　antigen　in　pa－
　tients　w th　bronchial　asthma　一statistical
　analysis　一．　J．　J．　T．　D．，　24　：　150　一　155，
　1986　（in　Japanese）．
カンジダ特異的lgG4抗体と気管支喘息
谷崎勝朗，貴谷光，岡崎守宏，御揃尚志，光延
文裕，高取明正1），奥田博之1）i原田英雄2）
岡山大学医学部附属病院三朝分院内科，1）産科婦
人科，2）環境病態研究施設成人病学分野
　66例の気管支喘息症例を対象に，血清中カンジ
ダ特異的lgG　4抗体を測定し，その血中レベル
と年齢および喘息の重症度との関連について検討
を加えた。
1．血清pンジダ特異的lgG4値は，0～39才，
40～59才の年齢層にくらべ，60才以上の年齢層に
おいて高く，年齢によりその値が変動することが
示唆された。
2．40～59才の年齢層では，血清カンジダ特異的
IgG　4は，ステロイド将士用例にくらべ，ステ
ロイド依存性重症難治性喘息症例で有意の高値を
示し，この年齢層では，カンジダ特異的lgG4
抗体がその発症病態に関連している可能性が示唆
された。
　以上，カンジダ特異的lgG4抗体の上昇は，
高年齢層の症例（60才以上）では全般的に，また
40～59才の年齢層で重症型喘息症例において観察
されることが明らかにされた。
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